A team of Columbia physician-scientists have opened a trial of a noninvasive, focused ultrasound approach to open the blood-brain barrier to better treat pediatric brain tumors.
Tannishtha Reya, PhD, is establishing the new Irving Cancer Drug Discovery Program, devoted to helping faculty accelerate research discoveries in their labs to the clinic.
Dr. Jeffrey Bruce: "This new approach has the potential to transform treatment for patients with brain cancer, where the outlook for survival remains very poor."
Melissa Accordino, MD, tackles solutions to long-term side effects, like peripheral neuropathy, that some breast cancer survivors experience after overcoming the disease.
During First Lady Jill Biden's Columbia Sept. 21 visit, she singles out patient, Mario Sambula and his special connection with clinical trials nurse navigator, Brianne Bodin.
As part of the Biden Administration's Cancer Moonshot initiative, First Lady Jill Biden and Queen Letizia of Spain visited Columbia University's cancer center on Sept. 21.
First Lady Jill Biden and Queen Letizia of Spain underscore Columbia Cancer's work in addressing health inequities, improving diversity in clinical trials and advancing critical cancer research.
Dr. Andrew Lassman: "These trials transformed our understanding of the clinical behavior of molecularly defined gliomas and contributed to the classification of gliomas used globally today."
A study, led by Dr. Dawn Hershman, tested whether standing orders embedded in electronic medical records systems could improve prescribing practice for CSFs and lower incidence of febrile neutropenia.
A new study led by Dr. Andrew Lassman addresses safety and efficacy of infigratinib, a fibroblast growth factor receptor (FGFR)-tyrosine kinase inhibitor, for patients with recurrent glioblastomas.